NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis $0.72 -0.03 (-4.45%) (As of 09/6/2024 08:48 PM ET) Add Compare Share Share Today's Range$0.70▼$0.7750-Day Range$0.57▼$1.0752-Week Range$0.55▼$7.45Volume29,600 shsAverage Volume96,899 shsMarket Capitalization$3.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Hepion Pharmaceuticals alerts: Email Address Ad InvestorPlace44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.The information in this video is crucially valuable. About Hepion Pharmaceuticals Stock (NASDAQ:HEPA)Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Read More HEPA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEPA Stock News HeadlinesSeptember 4, 2024 | globenewswire.comPharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed MergerAugust 14, 2024 | finance.yahoo.com336.SG,0P00015I0V,0 (336.SG)September 9, 2024 | InvestorPlace (Ad)44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.August 13, 2024 | uk.finance.yahoo.comHepatitis B Virus Infection Pipeline Insight Report 2024: Therapeutic Assessment of 80+ Companies and 90+ DrugsAugust 1, 2024 | finance.yahoo.comHepatic Tumor Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the DomainJuly 23, 2024 | theglobeandmail.comOligonucleotide Therapy Market to Reach USD 19.92 Billion by 2031 | InsightAce AnalyticJuly 23, 2024 | wsj.comHepion Pharmaceuticals Inc. Pfd.July 22, 2024 | benzinga.comFatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug DeveloperSeptember 9, 2024 | InvestorPlace (Ad)44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.July 22, 2024 | finance.yahoo.comPharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private PlacementJuly 22, 2024 | benzinga.comFatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug DeveloperMay 21, 2024 | investorplace.comHEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024April 28, 2024 | nytimes.comU.S. Lags Behind Other Countries in Hepatitis-C TreatmentApril 22, 2024 | finance.yahoo.comWhy Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 21, 2024 | stockhouse.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 20, 2024 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialSee More Headlines Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/09/2024Next Earnings (Estimated)11/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HEPA CUSIPN/A CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees20Year Founded2013Profitability EPS (Most Recent Fiscal Year)($9.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-408.98% Return on Assets-174.30% Debt Debt-to-Equity RatioN/A Current Ratio5.62 Quick Ratio5.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book2.26Miscellaneous Outstanding Shares5,473,000Free Float5,366,000Market Cap$3.96 million OptionableNo Data Beta1.85 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. John T. Cavan (Age 66)Interim CEO & CFO Comp: $495.33kSharen PyatetskayaDirector of Investor RelationsDr. John Z. Sullivan-Bolyai (Age 76)Part-Time Consultant Dr. Stephen A. Harrison FACPM.D., Scientific Advisory Board Chair & Consultant Medical DirectorKey CompetitorsImunonNASDAQ:CLSNKALA BIONASDAQ:KALATalpheraNASDAQ:TLPHSynlogicNASDAQ:SYBXBioVieNASDAQ:BIVIView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 126,000 shares on 8/15/2024Ownership: 9.428%Peter WijngaardBought 2,500 shares on 11/27/2023Total: $7,625.00 ($3.05/share)Peter WijngaardBought 2,500 shares on 11/24/2023Total: $7,725.00 ($3.09/share)Peter WijngaardBought 1,000 shares on 9/19/2023Total: $5,640.00 ($5.64/share)Robert T FosterBought 1,600 shares on 9/18/2023Total: $8,960.00 ($5.60/share)View All Insider TransactionsView All Institutional Transactions HEPA Stock Analysis - Frequently Asked Questions How have HEPA shares performed this year? Hepion Pharmaceuticals' stock was trading at $3.24 on January 1st, 2024. Since then, HEPA shares have decreased by 77.6% and is now trading at $0.7244. View the best growth stocks for 2024 here. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) posted its earnings results on Tuesday, August, 13th. The company reported ($0.68) EPS for the quarter. When did Hepion Pharmaceuticals' stock split? Hepion Pharmaceuticals shares reverse split before market open on Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Hepion Pharmaceuticals' major shareholders? Hepion Pharmaceuticals' top institutional investors include Armistice Capital LLC (9.43%). Insiders that own company stock include Robert T Foster and Peter Wijngaard. View institutional ownership trends. How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC), Axsome Therapeutics (AXSM), Archrock (AROC), Alector (ALEC) and AIM ImmunoTech (AIM). This page (NASDAQ:HEPA) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEPA Stock Alerts